Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Pronk, Marja H.
345  Ergebnisse:
Personensuche X
?
1

A Dutch cost-effectiveness analysis of fremanezumab versus ..:

Wolters, Sharon ; Carpay, Johannes A. ; Pronk, Marja H....
BMC Neurology.  24 (2024)  1 - p. , 2024
Link: https://doi.org/10.1186/..
 
?
2

Clinical and economic issues complicating cost-effectivenes..:

Nuijten, Mark J.C. ; Pronk, Marja H. ; Hutton, John...
The EuroBiotech Journal.  1 (2017)  2 - p. 132-137 , 2017
Link: https://doi.org/10.24190..
 
?
3

Out-Patient Drug Policy by Clinical Assessment Rather Than ..:

Pronk, Marja H. ; Bonsel, Gouke J.
The European Journal of Health Economics.  5 (2004)  3 - p. 274-277 , 2004
Link: https://www.jstor.org/st..
 
?
4

Out-patient drug policy by clinical assessment rather than ..:

Pronk, Marja H. ; Bonsel, Gouke J.
The European Journal of Health Economics, formerly: HEPAC.  5 (2004)  3 - p. 274-277 , 2004
Link: https://doi.org/10.1007/..
 
?
5

Introduction to the Pharmacoeconomics of Herbal Medicines:

De Smet, Peter A.G.M. ; Bonsel, Gouke ; Van der Kuy, Ary...
PharmacoEconomics.  18 (2000)  1 - p. 1-7 , 2000
Link: https://doi.org/10.2165/..
 
?
6

Reporting Format for Economic Evaluation: Part I: Applicati..:

Nuijten, Mark J.C. ; Brorens, Mark J.A. ; Hekster, Yechiel A....
PharmacoEconomics.  14 (1998)  2 - p. 159-163 , 1998
Link: https://doi.org/10.2165/..
 
?
7

Reporting Format for Economic Evaluation: Part II: Focus on..:

Nuijten, C ; Pronk, Marja H. ; Brorens A., Mark J....
PharmacoEconomics.  14 (1998)  3 - p. 259-268 , 1998
Link: https://doi.org/10.2165/..
 
?
8

Clinical and economic issues complicating cost-effectivenes..:

Nuijten Mark J.C ; Pronk Marja H ; Hutton John...
https://doi.org/10.24190/ISSN2564-615X/2017/02.04.  , 2017
Link: https://doi.org/10.24190..
 
?
9

Use of the kinetically-derived maximum dose concept in sele..:

Heringa, Minne B. ; Cnubben, Nicole H.P. ; Slob, Wout...
Regulatory Toxicology and Pharmacology.  114 (2020)  - p. 104659 , 2020
Link: https://doi.org/10.1016/..
 
?
10

Rebuttal to the letter to the editors regarding Heringa et ..:

Heringa, Minne B. ; Cnubben, Nicole H.P. ; Slob, Wout...
Regulatory Toxicology and Pharmacology.  116 (2020)  - p. 104730 , 2020
Link: https://doi.org/10.1016/..
 
?
11

Regulating human safety: How dose selection in toxicity stu..:

Woutersen, Marjolijn ; Muller, Andre ; Pronk, Marja E.J...
Regulatory Toxicology and Pharmacology.  114 (2020)  - p. 104660 , 2020
Link: https://doi.org/10.1016/..
 
?
12

Rebuttal to the letters to the editors by Terry et al. and ..:

Heringa, Minne B. ; Cnubben, Nicole H.P. ; Slob, Wout...
Regulatory Toxicology and Pharmacology.  118 (2020)  - p. 104803 , 2020
Link: https://doi.org/10.1016/..
 
?
13

The european union risk assessment on zinc and zinc compoun..:

Bodar, Charles W.M. ; Pronk, Marja E.J. ; Sijm, Dick T.H.M.
Integrated Environmental Assessment and Management.  1 (2005)  4 - p. 301-319 , 2005
Link: https://doi.org/10.1002/..
 
?
14

The European Union Risk Assessment on Zinc and Zinc Compoun..:

Charles W. M. Bodar ; Marja E. J. Pronk ; Dick T. H. M. Sijm , 2005
Link: https://bioone.org/doi/1..
 
?
15

Synthetic turf pitches with rubber granulate infill: are th..:

Pronk, Marja E. J. ; Woutersen, Marjolijn ; Herremans, Joke M. M.
Journal of Exposure Science & Environmental Epidemiology.  30 (2018)  3 - p. 567-584 , 2018
Link: https://doi.org/10.1038/..
 
1-15